牛牛AI助理已提取核心訊息
Allarity Therapeutics, Inc. has filed an amended Schedule 13G/A with the Securities and Exchange Commission (SEC) on February 12, 2024, indicating a change in ownership by certain reporting persons. The filing was made by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively referred to as the Reporting Persons, who now collectively own 653,377 shares of Allarity Therapeutics' common stock, representing 9.9% of the company. This ownership percentage is based on 5,886,934 outstanding shares as reported in the company's preliminary proxy statement filed on January 26, 2024. The shares include potential conversions and exercises of preferred stock, warrants, and a senior convertible note, all subject to beneficial ownership blockers that prevent ownership exceeding certain thresholds. The Reporting Persons have entered into a Joint Filing Agreement and have shared power to vote and dispose of the shares. The filing updates beneficial ownership information and amends previous disclosures, without indicating any intention to change or influence the control of Allarity Therapeutics.
Allarity Therapeutics, Inc. has filed an amended Schedule 13G/A with the Securities and Exchange Commission (SEC) on February 12, 2024, indicating a change in ownership by certain reporting persons. The filing was made by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively referred to as the Reporting Persons, who now collectively own 653,377 shares of Allarity Therapeutics' common stock, representing 9.9% of the company. This ownership percentage is based on 5,886,934 outstanding shares as reported in the company's preliminary proxy statement filed on January 26, 2024. The shares include potential conversions and exercises of preferred stock, warrants, and a senior convertible note, all subject to beneficial ownership blockers that prevent ownership exceeding certain thresholds. The Reporting Persons have entered into a Joint Filing Agreement and have shared power to vote and dispose of the shares. The filing updates beneficial ownership information and amends previous disclosures, without indicating any intention to change or influence the control of Allarity Therapeutics.
Allarity Therapeutics, Inc.已於2024年2月12日向美國證券交易委員會（SEC）提交了經修訂的附表13G/A，表明某些申報人的所有權發生了變化。該文件由3i、LP、3i Management LLC和Maier Joshua Tarlow提交，他們統稱爲申報人，他們現在共擁有Allarity Therapeutics的653,377股普通股，佔該公司的9.9％的股份。該所有權百分比基於該公司於2024年1月26日提交的初步委託書中報告的5,886,934股已發行股份。這些股票包括優先股、認股權證和優先可轉換票據的潛在轉換和行使，所有這些都受實益所有權封鎖的約束，以防止所有權超過一定門檻。申報人已簽訂聯合申報協議，並擁有投票和處置股份的共同權力。該文件更新了受益所有權信息並修改了先前的披露，但沒有表示有任何改變或影響Alarity Therapeutics控制權的意圖。
Allarity Therapeutics, Inc.已於2024年2月12日向美國證券交易委員會（SEC）提交了經修訂的附表13G/A，表明某些申報人的所有權發生了變化。該文件由3i、LP、3i Management LLC和Maier Joshua Tarlow提交，他們統稱爲申報人，他們現在共擁有Allarity Therapeutics的653,377股普通股，佔該公司的9.9％的股份。該所有權百分比基於該公司於2024年1月26日提交的初步委託書中報告的5,886,934股已發行股份。這些股票包括優先股、認股權證和優先可轉換票據的潛在轉換和行使，所有這些都受實益所有權封鎖的約束，以防止所有權超過一定門檻。申報人已簽訂聯合申報協議，並擁有投票和處置股份的共同權力。該文件更新了受益所有權信息並修改了先前的披露，但沒有表示有任何改變或影響Alarity Therapeutics控制權的意圖。
有用
沒用